Gara Jalqabaatti › Saree Oljoo › Texas › Houston
Qorannoo klinikaalii Saree Oljoo Houston, TX keessatti
Qorannoo 126 Saree Oljoo f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Houston
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Houston Methodist Hospital Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
A Study of PHST001 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements
Namoota walitti qabaa jiraQorannoo ilaalaa
- UT MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Kelsey Seybold Clinic, Houston
- University of Texas, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- UT MD Anderson Cancer Center, Houston
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Houston
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Texas Oncology Gulf Coast, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center, Houston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Namoota walitti qabaa jiraSadarkaa 1/2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Houston
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas Md Anderson Cancer Center, Houston
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas Md Anderson Cancer Center, Houston
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- Oncology Consultants P.A. ( Site 0061), Houston
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
Namoota walitti qabaa jiraSadarkaa 2/3
- M D Anderson Cancer Center, Houston
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
Namoota walitti qabaa jira
- The University of Texas M. D. Anderson Cancer Center, Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Houston Methodist Hospital, Houston
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Namoota walitti qabaa jira
- Houston Methodist Hospital, Houston
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, Houston
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Namoota walitti qabaa jira
- Baylor College of Medicine, Houston
- MD Anderson Cancer Clinic - Mays Clinic, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Baylor College of Medicine, Houston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- The University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
Namoota walitti qabaa jira
- Baylor Medicine, Houston
- MD Anderson Cancer Center, Houston
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Namoota walitti qabaa jiraSadarkaa 1
- M D Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Namoota walitti qabaa jiraSadarkaa 2
- Baylor College of Medicine, Houston
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Oncology Consultants PA, Houston
- Oncology Consultants PA, Houston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Oncology Consultants, P.A., Houston
- The University of Texas MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
- fi 1 dabalataa
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Md Anderson Cancer Center, Houston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Houston
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Namoota walitti qabaa jiraSadarkaa 2
- Houston Methodist Hospital ( Site 0022), Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Oncology Consultants, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center - University of Texas, Houston
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Oncology Consultants PA, Houston
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UT MD Anderson, Houston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas - MD Anderson Cancer Center, Houston
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas-MD Anderson, Houston
- Lumi Research, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- UT Health Houston, Houston
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- M. D. Anderson Cancer Center, Houston
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Namoota walitti qabaa jiraQorannoo ilaalaa
- MD Anderson Cancer Center, Houston
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Lyndon Baines Johnson General Hospital, Houston
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- fi 5 dabalataa
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center Uni of Te, Houston
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Namoota walitti qabaa jiraSadarkaa 2
- Baylor College of Medicine, Houston
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson, Houston
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Namoota walitti qabaa jiraSadarkaa 1
- M D Anderson Cancer Center, Houston
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
Namoota walitti qabaa jira
- The University of Texas M. D. Anderson Cancer Center, Houston
Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- M D Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- (USOR) Texas Oncology, Houston
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- MD Anderson Cancer Center, Houston
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
Namoota walitti qabaa jiraQorannoo ilaalaa
- MD Anderson Cancer Center, Houston
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UT MD Anderson Cancer Center, Houston
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- The University of Texas MD Anderson Cancer Center, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Namoota walitti qabaa jiraSadarkaa 2
- UT MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Namoota walitti qabaa jiraSadarkaa 2
- University of Texas MD Anderson Cancer Center, Houston
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Namoota walitti qabaa jiraSadarkaa 1
- M D Anderson Cancer Center, Houston
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas MD Anderson Cancer Center, Houston
Improving Comprehensive Care of Cancer Patients
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Baylor College of Medicine, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson, Houston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
Namoota walitti qabaa jiraSadarkaa 3
- M D Anderson Cancer Center, Houston
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Baylor College of Medicine, Houston
- MD Anderson Cancer Center, Houston
- Harris Health System - Smith Clinic, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Namoota walitti qabaa jiraSadarkaa 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Multi-center MRD Registry for Inflammatory Breast Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- MD Anderson Cancer Center, Houston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Namoota walitti qabaa jiraSadarkaa 3
- University of Texas MD Anderson Cancer Center, Houston
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- University of Texas MD Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- M D Anderson Cancer Center, Houston
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Houston Methodist Hospital, Houston
- M D Anderson Cancer Center, Houston
- Methodist Willowbrook Hospital, Houston
- fi 2 dabalataa
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
- MD Anderson in Katy, Houston
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Oncology Consultants, Houston
- Next Oncology, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Md Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Baylor St. Luke's Medical Center, Houston
Converting HR+ Breast Cancer Into an Individualized Vaccine
Namoota walitti qabaa jiraSadarkaa 2
- Houston Methodist Cancer Center, Houston
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Namoota walitti qabaa jiraQorannoo ilaalaa
- The University of Texas MD Anderson Cancer Center, Houston
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Namoota walitti qabaa jira
- Baylor St Luke's Medical Centre, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas M.D. Anderson Cancer Center, Houston
TRUDI: TDXD+Durva in HER2+/Low IBC
Namoota walitti qabaa jiraSadarkaa 2
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #1, Houston
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Namoota walitti qabaa jiraQorannoo ilaalaa
- Texas Oncology - Memorial City, Houston
- Texas Oncology Willowbrook, Houston
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Biotheryx Investigative Site, Houston
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Oncology Consultants, Houston
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Namoota walitti qabaa jiraQorannoo ilaalaa
- The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Namoota walitti qabaa jiraSadarkaa 3
- Baylor College Of Medicine, Houston
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
- Arlington, VAQorannoo 47
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 47
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.